Q-omics provides the consensus-scored GEMIN7 profile across patient tissues and cancer cell-line models. GEMIN7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GEMIN7 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, GEMIN7 RNA expression shows 18,793 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRC, and ACC as cancer lineages where GEMIN7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GEMIN7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GEMIN7 survival associations across molecular data types. GEMIN7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GEMIN7 RNA expression–survival associations across cancer types. High GEMIN7 expression shows unfavorable associations in LIHC, MESO, ACC, HNSC, KIRP and KICH. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GEMIN7 RNA expression.
This table summarizes GEMIN7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GEMIN7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GEMIN7 shows higher tumor expression in KIRC, BLCA, HNSC, LIHC, KIRP and LUAD. The KIRC box plot shows higher GEMIN7 RNA expression in tumor versus normal tissue (log2 FC = +0.840, t-test p < 0.001).
This table shows molecular features associated with GEMIN7 in patient tissues and cancer cell lines. In patient samples, GEMIN7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GEMIN7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
